vs
Side-by-side financial comparison of OneStream, Inc. (OS) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
PTC THERAPEUTICS, INC. is the larger business by last-quarter revenue ($164.7M vs $163.7M, roughly 1.0× OneStream, Inc.). OneStream, Inc. runs the higher net margin — 0.6% vs -82.0%, a 82.6% gap on every dollar of revenue. On growth, OneStream, Inc. posted the faster year-over-year revenue change (23.6% vs -22.7%). OneStream, Inc. produced more free cash flow last quarter ($25.6M vs $-36.6M). Over the past eight quarters, OneStream, Inc.'s revenue compounded faster (21.8% CAGR vs -11.5%).
Blue Stream provides cable television, cable telephone, DVR, and up to 1 GIG Internet speed broadband services to customers in the Florida communities of Coral Springs and Weston.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
OS vs PTCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $163.7M | $164.7M |
| Net Profit | $999.0K | $-135.0M |
| Gross Margin | 69.8% | — |
| Operating Margin | -3.2% | -43.3% |
| Net Margin | 0.6% | -82.0% |
| Revenue YoY | 23.6% | -22.7% |
| Net Profit YoY | — | -104.8% |
| EPS (diluted) | — | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $163.7M | $164.7M | ||
| Q3 25 | $154.3M | $211.0M | ||
| Q2 25 | $147.6M | $178.9M | ||
| Q1 25 | $136.3M | $1.2B | ||
| Q4 24 | $132.5M | $213.2M | ||
| Q3 24 | $129.1M | $196.8M | ||
| Q2 24 | $117.5M | $186.7M | ||
| Q1 24 | $110.3M | $210.1M |
| Q4 25 | $999.0K | $-135.0M | ||
| Q3 25 | $-8.8M | $15.9M | ||
| Q2 25 | $-18.4M | $-64.8M | ||
| Q1 25 | $-24.0M | $866.6M | ||
| Q4 24 | — | $-65.9M | ||
| Q3 24 | $-171.9M | $-106.7M | ||
| Q2 24 | $-7.8M | $-99.2M | ||
| Q1 24 | $-5.0M | $-91.6M |
| Q4 25 | 69.8% | — | ||
| Q3 25 | 68.1% | — | ||
| Q2 25 | 68.6% | — | ||
| Q1 25 | 68.0% | — | ||
| Q4 24 | 66.8% | — | ||
| Q3 24 | 50.1% | — | ||
| Q2 24 | 68.5% | — | ||
| Q1 24 | 69.1% | — |
| Q4 25 | -3.2% | -43.3% | ||
| Q3 25 | -11.3% | 1.4% | ||
| Q2 25 | -21.8% | -19.5% | ||
| Q1 25 | -29.3% | 82.5% | ||
| Q4 24 | -35.8% | -76.2% | ||
| Q3 24 | -197.6% | -27.7% | ||
| Q2 24 | -9.8% | -21.5% | ||
| Q1 24 | -4.9% | -21.6% |
| Q4 25 | 0.6% | -82.0% | ||
| Q3 25 | -5.7% | 7.5% | ||
| Q2 25 | -12.5% | -36.3% | ||
| Q1 25 | -17.6% | 73.7% | ||
| Q4 24 | — | -30.9% | ||
| Q3 24 | -133.1% | -54.2% | ||
| Q2 24 | -6.7% | -53.1% | ||
| Q1 24 | -4.5% | -43.6% |
| Q4 25 | — | $-1.63 | ||
| Q3 25 | — | $0.20 | ||
| Q2 25 | — | $-0.83 | ||
| Q1 25 | — | $10.04 | ||
| Q4 24 | — | $-0.85 | ||
| Q3 24 | $-1.06 | $-1.39 | ||
| Q2 24 | — | $-1.29 | ||
| Q1 24 | — | $-1.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $693.6M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $504.7M | $-205.3M |
| Total Assets | $1.0B | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $693.6M | $1.9B | ||
| Q3 25 | $653.9M | $1.7B | ||
| Q2 25 | $652.1M | $2.0B | ||
| Q1 25 | $593.9M | $2.0B | ||
| Q4 24 | $544.2M | $1.1B | ||
| Q3 24 | $495.5M | $1.0B | ||
| Q2 24 | $140.5M | $1.1B | ||
| Q1 24 | — | $884.8M |
| Q4 25 | $504.7M | $-205.3M | ||
| Q3 25 | $472.1M | $-155.8M | ||
| Q2 25 | $458.2M | $-206.5M | ||
| Q1 25 | $412.9M | $-185.8M | ||
| Q4 24 | $386.2M | $-1.1B | ||
| Q3 24 | $458.2M | $-1.1B | ||
| Q2 24 | $97.5M | $-980.2M | ||
| Q1 24 | $102.5M | $-893.9M |
| Q4 25 | $1.0B | $2.9B | ||
| Q3 25 | $949.4M | $2.6B | ||
| Q2 25 | $910.5M | $2.6B | ||
| Q1 25 | $867.3M | $2.7B | ||
| Q4 24 | $823.2M | $1.7B | ||
| Q3 24 | $750.1M | $1.8B | ||
| Q2 24 | $379.7M | $1.9B | ||
| Q1 24 | — | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $25.8M | $-34.3M |
| Free Cash FlowOCF − Capex | $25.6M | $-36.6M |
| FCF MarginFCF / Revenue | 15.7% | -22.3% |
| Capex IntensityCapex / Revenue | 0.1% | 1.4% |
| Cash ConversionOCF / Net Profit | 25.79× | — |
| TTM Free Cash FlowTrailing 4 quarters | $95.6M | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $25.8M | $-34.3M | ||
| Q3 25 | $5.0M | $-66.3M | ||
| Q2 25 | $29.7M | $-58.3M | ||
| Q1 25 | $36.2M | $870.1M | ||
| Q4 24 | — | $-30.0M | ||
| Q3 24 | $2.4M | $-77.0M | ||
| Q2 24 | $8.1M | $-71.5M | ||
| Q1 24 | $25.5M | $70.8M |
| Q4 25 | $25.6M | $-36.6M | ||
| Q3 25 | $4.8M | $-69.7M | ||
| Q2 25 | $29.4M | $-59.6M | ||
| Q1 25 | $35.8M | $868.4M | ||
| Q4 24 | — | $-33.8M | ||
| Q3 24 | $1.3M | $-77.5M | ||
| Q2 24 | $7.7M | $-78.8M | ||
| Q1 24 | $24.9M | $61.2M |
| Q4 25 | 15.7% | -22.3% | ||
| Q3 25 | 3.1% | -33.1% | ||
| Q2 25 | 19.9% | -33.3% | ||
| Q1 25 | 26.3% | 73.8% | ||
| Q4 24 | — | -15.8% | ||
| Q3 24 | 1.0% | -39.4% | ||
| Q2 24 | 6.6% | -42.2% | ||
| Q1 24 | 22.5% | 29.1% |
| Q4 25 | 0.1% | 1.4% | ||
| Q3 25 | 0.1% | 1.6% | ||
| Q2 25 | 0.2% | 0.7% | ||
| Q1 25 | 0.3% | 0.1% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | 0.8% | 0.3% | ||
| Q2 24 | 0.3% | 4.0% | ||
| Q1 24 | 0.6% | 4.6% |
| Q4 25 | 25.79× | — | ||
| Q3 25 | — | -4.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OS
| Subscription And Circulation | $150.3M | 92% |
| Professional Services And Other | $9.4M | 6% |
| License | $4.0M | 2% |
PTCT
Segment breakdown not available.
